PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectiou...(registered under the Securities Act of 1...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
Date:9/30/2008
registered under the Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. PharmAthene has agreed to file a registration statement under the Securities Act to register the shares of common stock to be issued at closing and upon any exercise of the warrants for public resale from time to time in the future. There can be no assurances that the registration statement will be declared effective. The information contained in this press release does not constitute an offer for the sale of any securities.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States
and its allies by developing and commercializing medical countermeasures
against biological and chemical weapons. PharmAthene's lead product
development programs include:
-- SparVax(TM) - a second generation recombinant protective antigen (rPA)
anthrax vaccine
-- Third generation rPA anthrax vaccine
-- Valortim(R) - a fully human monoclonal antibody for the prevention and
treatment of anthrax infection
-- Protexia(R) - a novel bioscavenger for the prevention and treatment of
morbidity and mortality associated with exposure to chemical nerve
agents
-- RypVax(TM) - a recombinant dual antigen vaccine for plague
For more information about PharmAthene, please visit http://www.PharmAthene.com.
About Panacea Biotec Ltd.
Panacea Biotec is an Indian research-based health management company
with established research, manufacturing and marketing capabilities.
Panacea Biotec's product portfolio includes innovative prescription
products in important therapeutic areas such as pain management, diabetes
management, renal-disease management, anti-osteoporosis, anti-tubercualar,
gastro-intestinal c
'/>"/>
| SOURCE PharmAthene, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
Breaking Biology Technology:Marrone Bio Innovations Announces Two New Executive Appointments 2Marrone Bio Innovations Announces Two New Executive Appointments 3Endologix Appoints Dan Lemaitre to its Board of Directors 2Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4
Other Biology Technology:Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 2Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central Asia 3Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 2Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 3Frontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology Talent 4Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 2Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 3Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 4Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors 5
Health Robotics Expands i.v.STATION(TM) Partnership With Can-Med in 10 Countries Within Central AsiaFrontage Laboratories Continues to Grow Its China Business and Add Corporate Financial, Regulatory and Clinical Pharmacology TalentMicromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5Scientists identify natural anti-cancer defenses 2New management methods extend blackberry season 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 1PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 2PEAK Surgical and Medtronic Announce Global Distribution Agreement for the Ear Nose and Throat Market 5231 3Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 1Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 2Kimberly Clark Acquires Baylis Medical Companys Pain Management Business 5227 3Blue Shield of California Awards 2429 6 Million in Pay for Performance Programs in 2009 5223 1Blue Shield of California Awards 2429 6 Million in Pay for Performance Programs in 2009 5223 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |